UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Curious about long-term investing? Learn essential insights that will help you navigate the investment landscape effectively.
27,039 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Amazon is edging toward a $3 trillion market cap as cloud growth and aggressive capital spending power a potential mi...
As a new Fed chair, chair kevin warsh will confront two high-stakes tests in just 100 days. One test centers on polit...
A key on-chain signal points to a potential drop toward $700 for ethereum (eth), even as network activity grows and i...
Amazon delivered a blockbuster Q1 2026, but a record capex plan raises questions about the stock’s two-year path. Her...
Apple sticks to an asset-light model with robust buybacks, while Microsoft escalates capital spending to fuel AI and ...
Dram stocks surged on AI-driven demand, yet the rally carries volatility and a stubborn supply gap. This analysis exp...
Trump unveils a plan to monetize passage through the Strait of Hormuz, triggering market moves and raising questions ...
A surge in people choosing to rent is changing the game for real estate investors. This article breaks down loan stra...
MercadoLibre faced a sharp price move after a quarter that showed strong top-line momentum but weaker profitability. ...
A Goldman Sachs note presents a bullish scenario where gold could hit $5,400 per ounce. The outlook reverberates thro...
Freddie Mac data show mortgage rates climbed to their highest level in almost four months, pushing the 30-year loan t...